ReviewCurrent atherosclerosis reports2013
The cholesterol emboli syndrome in atherosclerosis.
Review in Current atherosclerosis reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review.Rheumatology (Oxford, England) · 2022Pooled it
- Analysis of the clinical characteristics of warfarin-associated purple toe syndrome.Clinical and experimental medicine · 2026Article
- Progressive Cutaneous Cholesterol Emboli Syndrome.Cureus · 2025Article
- Blue toe syndrome caused by cholesterol crystal embolisation in a patient with warfarin use.BMJ case reports · 2023Article
- Coronary No-Reflow after Primary Percutaneous Coronary Intervention-Current Knowledge on Pathophysiology, Diagnosis, Clinical Impact and Therapy.Journal of clinical medicine · 2023Review
- Formation and Cellular Impact of Cholesterol Crystals in Health and Disease.Advanced biology · 2021Review
- Article
- Effect of Atheromatous Aorta on Thromboembolic Complications after Endovascular Aortic Aneurysm.Annals of vascular diseases · 2020Article
- Acalculous Cholecystitis Complicated by Liver Abscess as a Manifestation of Cholesterol Embolization Syndrome - Infrequent Manifestation Precipitated by a Common Procedure.European journal of case reports in internal medicine · 2020Article
- A rare case of spontaneous renal cholesterol crystallization embolism.Chinese medical journal · 2019Article
- Cholesterol-embolization syndrome: current perspectives.Vascular health and risk management · 2019Review
- The usefulness of Duplex Doppler ultrasound in the angiological and dermatological diagnosis of patients with blue toe syndrome.Postepy dermatologii i alergologii · 2017Article
- Quantitative Analysis of Lipid-Rich Necrotic Core in Carotid Atherosclerotic Plaques by In Vivo Magnetic Resonance Imaging and Clinical Outcomes.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Cholesterol Crystal Embolism and Chronic Kidney Disease.International journal of molecular sciences · 2017Review
- Performing Anticoagulation: A Puzzling Case of Cholesterol Embolization Syndrome.Clinical medicine insights. Case reports · 2017Article
- Anti-neutrophil cytoplasmic antibodies in cholesterol embolism: A case report and literature review.Experimental and therapeutic medicine · 2016Article
- Association between absolute blood eosinophil count and CKD stages among cardiac patients.Heart and vessels · 2016Article
- Treatment of Cholesterol Embolization Syndrome in the Setting of an Acute Indication for Anticoagulation Therapy.Journal of medical cases · 2014Article
- Blue Toe Syndrome: A Challenging Diagnosis.Indian journal of dermatologyArticle
- Cholesterol crystal embolism to the gastrointestinal tract: a catastrophic case.Autopsy & case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholesterol emboli syndrome is a relatively rare, but potentially devastating, manifestation of atherosclerotic disease. Cholesterol emboli syndrome is characterized by waves of arterio-arterial embolization of cholesterol crystals and atheroma debris from atherosclerotic plaques in the aorta or its large branches to small or medium caliber arteries (100-200 μm in diameter) that frequently occur after invasive arterial procedures. End-organ damage is due to mechanical occlusion and inflammatory response in the destination arteries. Clinical manifestations may include renal failure, blue toe syndrome, global neurologic deficits and a variety of gastrointestinal, ocular and constitutional signs and symptoms. There is no specific therapy for cholesterol emboli syndrome. Supportive measures include modifications of risk factors, use of statins and antiplatelet agents, avoidance of anticoagulation and thrombolytic agents, and utilization of surgical and endovascular techniques to exclude sources of cholesterol emboli.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.